Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 12,830 shares at $20.08 ($257K) on 2025-05-01, disclosed to the SEC on 2025-05-05.
Scheduled sale ($257k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.08 | 5,330 | $107K | 41.6% |
| 2 | $20.08 | 5,330 | $107K | 41.6% |
| 3 | $20.00 | 2,170 | $43K | 16.9% |
| Total | $20.07 avg | 12,830 | $257K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |